The problem with this article, and with what some others are saying is that the 30.1 million figure includes the 15+ million we payed to GSK as part of the settled litigation. Add that to the revenues and you're over 45 million, which is a nice step up. Good investors read the entire 8k, and saw that. I have no worries of this stock again trading in the high 3's to low 4's over the coming days.
News 
Market Data 
Discover 
